Get the Stockscreener App
1.30
1.52%
-0.02
Lexicon Pharmaceuticals Inc stock is traded at $1.30, with a volume of 1.04M.
It is down -1.52% in the last 24 hours and down -15.58% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
See More
Previous Close:
$1.32
Open:
$1.32
24h Volume:
1.04M
Relative Volume:
0.47
Market Cap:
$472.42M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-1.625
EPS:
-0.8
Net Cash Flow:
$-162.37M
1W Performance:
-7.14%
1M Performance:
-15.58%
6M Performance:
+86.84%
1Y Performance:
+58.11%
1-Day Range:
$1.30
$1.35
1-Week Range:
$1.29
$1.4799
52-Week Range:
$0.2836
$1.66
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.30 | 479.69M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-17-24 | Initiated | H.C. Wainwright | Buy |
| Apr-30-24 | Initiated | Leerink Partners | Outperform |
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
Lexicon Pharmaceuticals to advance obesity treatment with new ACSL5 inhibitor data - Traders Union
Novo Nordisk (NVO) Collaborates with Lexicon on Obesity Treatmen - GuruFocus
Lexicon Pharmaceuticals Publishes Preclinical Data Supporting ACSL5 as Target for Obesity Treatment - Quiver Quantitative
Lexicon Pharmaceuticals (Nasdaq: LXRX) publishes ACSL5 obesity data supporting LX9851 - Stock Titan
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Clinical data on effect of sotagliflozin on adipose distribution in non-diabetic patients - marketscreener.com
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum - The Manila Times
Clinical Data On Effect Of Sotagliflozin On Adipose Distribution In Non-Diabetic Patients - TradingView
Lexicon Pharmaceuticals to Present Clinical Data on Sotagliflozin at CVCT 2025 Conference - Quiver Quantitative
Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development - MSN
Is Lexicon Pharmaceuticals Inc. stock attractive for ETFs2025 Key Highlights & Daily Profit Maximizing Trade Tips - Newser
Year in Review: Local co. striking deal worth up to $1B with Ozempic maker was a Deal of the Week - The Business Journals
Carcinoid Syndrome Market to Expand Significantly by 2034, - openPR.com
Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well - Seeking Alpha
Piper Sandler Healthcare Conference - marketscreener.com
Lexicon Pharmaceuticals (LXRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Will Lexicon Pharmaceuticals Inc. stock deliver long term returns2025 Market Overview & Fast Entry High Yield Stock Tips - moha.gov.vn
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences - The Manila Times
Lexicon Pharma (Nasdaq: LXRX) in Piper Sandler 37th and Evercore 8th investor events - Stock Titan
Would You Still Hold Lexicon Pharmaceuticals Stock If It Fell 30%? - Trefis
10 Fastest Growing Penny Stocks to Buy Now - Insider Monkey
Why Lexicon Pharmaceuticals Inc. stock is considered a top pick2025 Stock Rankings & Daily Market Momentum Tracking - newser.com
Can Lexicon Pharmaceuticals Inc. stock deliver consistent earnings growthWeekly Trend Recap & Reliable Intraday Trade Plans - newser.com
Will Lexicon Pharmaceuticals Inc. stock split attract more investorsBear Alert & Daily Price Action Insights - newser.com
Can Lexicon Pharmaceuticals Inc. stock resist market sell offs2025 Institutional Moves & Weekly Watchlist for Hot Stocks - newser.com
Can Lexicon Pharmaceuticals Inc. stock surprise with earnings upsideQuarterly Market Review & Accurate Buy Signal Notifications - newser.com
Transcript : Lexicon Pharmaceuticals, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 05 - MarketScreener
Is Lexicon Pharmaceuticals Inc. stock attractive for growth ETFs2025 Earnings Surprises & Verified Technical Trade Signals - newser.com
How to manage a losing position in Lexicon Pharmaceuticals Inc.Analyst Upgrade & Verified Entry Point Signals - newser.com
Lexicon Pharmaceuticals at Jefferies London: Strategic Pipeline Progress By Investing.com - Investing.com Canada
Xpeng, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Published on: 2025-11-16 06:10:48 - newser.com
Wall Street Zen Downgrades Lexicon Pharmaceuticals (NASDAQ:LXRX) to Hold - MarketBeat
Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win (NASDAQ:LXRX) - Seeking Alpha
Lexicon Pharmaceuticals backs Type 1 diabetes research ahead of World Diabetes Day - Traders Union
What the charts say about Lexicon Pharmaceuticals Inc. todayTake Profit & Real-Time Chart Breakout Alerts - newser.com
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):